Skin topical composition
By using nonionic surfactants in the composition of salicylic acid and benzethonium chloride, insoluble matter formation is prevented, maintaining clarity and effectiveness for anti-acne use.
Patent Information
- Application Number
- JP2020148631
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-09-05
- Filing Date
- 2020-09-04
- Publication Date
- 2024-11-27
- Estimated Expiration
- 2040-09-04
AI Technical Summary
The combination of salicylic acid and benzethonium chloride in aqueous solutions results in the formation of insoluble matter, affecting the appearance and potentially reducing the pharmacological effectiveness of the composition.
Incorporating a nonionic surfactant, such as polyoxyethylene hydrogenated castor oil, polyoxyethylene alkyl ether, or polyoxyethylene polyoxypropylene alkyl ether, into the composition to suppress the formation of insoluble substances.
The composition maintains clarity and stability, ensuring the active ingredients remain effective without chemical changes, suitable for anti-acne applications.
Smart Images

Figure 0007590833000001 
Figure 0007590833000002 
Figure 0007590833000003
Abstract
Description
[Technical field]
[0001] The present invention relates to a composition for external use on the skin which contains salicylic acid, benzethonium chloride and a nonionic surfactant. [Background technology]
[0002] Salicylic acid has the effect of softening keratin, opening pores and discharging clogged sebum. It is also known to have an antifungal effect, particularly inhibiting the growth of tinea fungus by 1000 to 4000 times (see, for example, Non-Patent Document 1).
[0003] Benzethonium chloride is a quaternary ammonium salt classified as a cationic surfactant (invert soap) and has a strong bactericidal effect against common bacteria (such as Escherichia coli and Staphylococcus aureus) (see, for example, Non-Patent Document 2).
[0004] In recent years, salicylic acid and benzethonium chloride have been widely used in pharmaceuticals and quasi-drugs for topical skin application for purposes such as anti-acne, sterilization, and anti-dermatitis as active ingredients that exhibit keratolytic and antibacterial / bactericidal effects, respectively.
[0005] Patent Document 1 discloses a preservative formulation comprising a synergistic mixture of (a) a benzethonium salt; and (b) (i) dehydroacetic acid or a salt thereof; and (ii) salicylic acid or a salt thereof, and describes that the salicylic acid and dehydroacetic acid enhance the fungicidal effect of the benzethonium salt. Patent Document 2 discloses a preservative formulation comprising a synergistic mixture of salicylic acid as an anti-acne agent, benzalkonium chloride as an antibacterial agent, and cetyl lactate, C 12-15 A composition is disclosed that comprises a lactate ester selected from alkyl lactates and combinations thereof. [Prior art documents] [Patent documents]
[0006] [Patent Document 1] Special Publication No. 2004-524320 (Patent No. 4361735) [Patent Document 2] JP 2006-22101 A (Patent No. 5047476) [Non-patent literature]
[0007] [Non-Patent Document 1] Pharmaceutical interview form (parasitic and keratotic skin disease drug, salicylic acid powder "Maruishi") January 2015 revised version (2nd edition) [Non-Patent Document 2] Pharmaceutical Interview Form (Japanese Pharmacopoeia Benzethonium Chloride Solution Hyamine Solution 10%) Revised March 2015 (4th edition) [Non-Patent Document 3] Mentholatum (registered trademark) Acnes (registered trademark) 25 Medical Lotion Package Insert (Rohto Pharmaceutical Co., Ltd.) [Non-Patent Document 4] Pair Acne Liquid Treatment Package Insert (Lion Corporation, revised March 2014) Summary of the Invention [Problem to be solved by the invention]
[0008] Anti-acne agents containing salicylic acid are commercially available (Non-Patent Documents 3 and 4), but it is expected that further effectiveness can be maintained if salicylic acid and benzethonium chloride can be combined at the same time. However, no anti-acne agent that combines these is known. Therefore, the present inventors attempted to create a skin topical composition that combines salicylic acid and benzethonium chloride.
[0009] However, the present inventors have found that insoluble matter is generated in an aqueous solution containing a combination of salicylic acid and a quaternary ammonium salt such as benzethonium chloride. The appearance of insoluble matter not only leads to a poor appearance of the preparation, but also raises concerns that the pharmacological effect that should be expected may not be fully obtained due to chemical changes in the active ingredient, etc.
[0010] The occurrence of insoluble matter by the combination of salicylic acid and benzethonium chloride was an unknown phenomenon prior to the filing of the present application, and therefore no method for suppressing the occurrence of insoluble matter was known. Thus, the present invention aims to provide a composition in which the occurrence of insoluble matter by the combination of salicylic acid and benzethonium chloride is suppressed. [Means for solving the problem]
[0011] As a result of intensive research to solve the above problems, the present inventors have succeeded in producing a composition in which the appearance of insoluble matters due to the combination of salicylic acid and benzethonium chloride is suppressed by using a nonionic surfactant. The present invention was completed based on the above findings.
[0012] That is, according to the present invention, the following inventions are provided. [1] A composition for external use on the skin comprising the following (a) to (c): (a) Salicylic acid (b) Benzethonium chloride (c) one or more nonionic surfactants selected from the group consisting of polyoxyethylene hydrogenated castor oil, polyoxyethylene alkyl ether, and polyoxyethylene polyoxypropylene alkyl ether. [2] The composition for external application to skin according to [1], wherein the content of the nonionic surfactant is 0.1 to 20% by mass of the entire composition for external application to skin.
[0013] [3] The composition for topical skin application described in [1] or [2], further containing allantoin. [4] The composition for external use on the skin described in any one of [1] to [3], further comprising a polyhydric alcohol. [5] The composition for external use on the skin described in any one of [1] to [4], further comprising a lower alcohol. [6] The composition for external use on the skin according to any one of [1] to [5], which is in the form of a liquid for external use, a cream, an ointment, a gel, a spray, a solid for external use, or a patch. [7] The composition for external application to the skin described in any one of [1] to [6], which is in the form of a liquid for external application. [8] The composition for external use on the skin described in any one of [1] to [7], which is for anti-acne purposes. [9] The composition for external application to skin described in any one of [1] to [8], contained in a polyolefin container. Effect of the Invention
[0014] In the composition for external use on the skin of the present invention, the appearance of insoluble matters due to the combination of salicylic acid and benzethonium chloride is suppressed. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0015] The following description of the present invention may be based on representative embodiments and specific examples, but the present invention is not limited to such embodiments. In this specification, a numerical range expressed using "~" means a range including the numerical values before and after "~" as the lower and upper limits. In this specification, "%" is based on mass unless otherwise specified.
[0016] The composition for external use on the skin of the present invention contains the following (a) to (c): (a) Salicylic acid (b) Benzethonium chloride (c) one or more nonionic surfactants selected from the group consisting of polyoxyethylene hydrogenated castor oil, polyoxyethylene alkyl ether, and polyoxyethylene polyoxypropylene alkyl ether.
[0017] The skin topical composition of the present invention is excellent in that the appearance of insoluble matter due to the combination of salicylic acid and benzethonium chloride is suppressed.In addition, the skin topical composition of the present invention can be stored while suppressing the appearance of insoluble matter due to the combination of salicylic acid and benzethonium chloride, and has excellent storage stability.The skin topical composition of the present invention can fully obtain the pharmacological effect that should be originally expected without decreasing the medicinal effect due to chemical changes of the active ingredient, etc.
[0018] The "salicylic acid" used in the skin external composition of the present invention is salicylic acid or a salt thereof, preferably salicylic acid or sodium salicylate, more preferably salicylic acid. The salicylic acid of the present invention is listed in the 17th edition of the Japanese Pharmacopoeia.
[0019] The composition for external use on the skin of the present invention may contain salicylic acid as component (a) in the range of 0.1 to 5% by mass, preferably 0.1 to 1% by mass, of the total composition.
[0020] "Benzethonium chloride" used in the topical skin composition of the present invention is listed in the 17th edition of the Japanese Pharmacopoeia.
[0021] The composition for external use on the skin of the present invention may contain benzethonium chloride as component (b) in the range of 0.01 to 2% by mass, preferably 0.01 to 0.5% by mass, of the total composition.
[0022] The skin topical composition of the present invention contains (a) salicylic acid and (b) benzethonium chloride, as well as (c) a nonionic surfactant. Nonionic surfactants are generally used in topical preparations as stabilizers, surfactants, solubilizers, bases, wetting agents, suspension (or coating) agents, emulsifiers, excipients, dispersants, disintegrants, disintegration aids, solubilizers, solubilization aids, and solvents, and specific examples of these are listed in the Pharmaceutical Additives Dictionary 2016.
[0023] The nonionic surfactant of component (c) that can be used in the skin topical composition of the present invention is one or more selected from the group consisting of polyoxyethylene hydrogenated castor oil, polyoxyethylene alkyl ether, and polyoxyethylene polyoxypropylene alkyl ether. The skin topical composition of the present invention may contain one or a combination of two or more selected from the group consisting of polyoxyethylene hydrogenated castor oil, polyoxyethylene alkyl ether, and polyoxyethylene polyoxypropylene alkyl ether as the nonionic surfactant.
[0024] In the present invention, the nonionic surfactant of component (c) can be used for the purpose of suppressing the appearance of insoluble matters in a composition containing salicylic acid and benzethonium chloride.
[0025] In the present invention, the polyoxyethylene hydrogenated castor oil that can be used as component (c) is not particularly limited, but may have an average number of moles of ethylene oxide added in the range of 10 to 100, preferably 20 to 80. In particular, the polyoxyethylene hydrogenated castor oil is preferably one having an average number of moles of ethylene oxide added of 10, 20, 30, 40, 50, 60, 70, or 80. The polyoxyethylene hydrogenated castor oil may be used alone or in combination of two or more kinds as the nonionic surfactant of component (c).
[0026] In the present invention, the polyoxyethylene alkyl ether that can be used as component (c) is not particularly limited, but can be a polyoxyethylene alkyl ether having an average number of moles of ethylene oxide added in a specific range, or a polyoxyethylene alkyl ether having an average number of moles of ethylene oxide added in a specific range and a carbon number of the alkyl group in a specific range. The average number of moles of ethylene oxide added in the polyoxyethylene alkyl ether that can be used in the present invention can be in the range of 2 to 50, and is preferably in the range of 4 to 30. In particular, the average number of moles of ethylene oxide added in the polyoxyethylene alkyl ether is preferably 2, 3, 4, 5, 6, 7, 9, 10, 12, 15, 20, 21, 23, 25, 30, 40, or 50. The carbon number of the alkyl group in the polyoxyethylene alkyl ether that can be used in the present invention can be in the range of 12 to 22. In particular, the carbon number of the alkyl group in the polyoxyethylene alkyl ether is preferably 12, 14, 16, 18, or 22. The polyoxyethylene alkyl ethers may be used alone or in combination of two or more as the component (c) nonionic surfactant.
[0027] In the present invention, the polyoxyethylene polyoxypropylene alkyl ether that can be used as component (c) is not particularly limited, and can be a polyoxyethylene polyoxypropylene alkyl ether in which the average number of moles of ethylene oxide and propylene oxide added is within a specific range, or can be a polyoxyethylene polyoxypropylene alkyl ether in which the average number of moles of ethylene oxide and propylene oxide added is within a specific range and the number of carbon atoms in the alkyl group is within a specific range. For the polyoxyethylene polyoxypropylene alkyl ether that can be used in the present invention, the average number of moles of ethylene oxide added is in the range of 1 to 30, preferably in the range of 10 to 20. Also, the average number of moles of propylene oxide added is in the range of 1 to 10, preferably in the range of 4 to 8. For the polyoxyethylene polyoxypropylene alkyl ether that can be used in the present invention, the number of carbon atoms in the alkyl group can be in the range of 12 to 22. In particular, for the polyoxyethylene polyoxypropylene alkyl ether, the number of carbon atoms in the alkyl group is preferably 12, 14, 16, 18, or 22. The polyoxyethylene polyoxypropylene alkyl ethers can be used either individually or in combination of two or more as the component (c) nonionic surfactant.
[0028] The content of the nonionic surfactant of component (c) in the skin topical composition of the present invention is not particularly limited, but is preferably in the range of 0.1 to 20% by mass of the entire composition, more preferably in the range of 0.5 to 10% by mass, and even more preferably in the range of 1 to 6% by mass. When two or more kinds of nonionic surfactants of component (c) are used, the above content range can be the total content of the two or more kinds of nonionic surfactants of component (c).
[0029] The skin topical composition of the present invention can be an aqueous composition. In the present invention, an aqueous composition means a composition containing water. The skin topical composition of the present invention can contain water in an amount of 5% by mass or more, 10% by mass or more, 15% by mass or more, 20% by mass or more, 25% by mass or more, 30% by mass or more, 35% by mass or more, 40% by mass or more, 45% by mass or more, 50% by mass or more, 55% by mass or more, 60% by mass or more, 65% by mass or more, 70% by mass or more, 75% by mass or more, 80% by mass or more, 85% by mass or more, 90% by mass or more, or 95% by mass or more of the total composition. The water used in the aqueous composition of the present invention is not particularly limited, but examples thereof include distilled water, ordinary water, purified water, sterilized purified water, water for injection, and distilled water for injection.
[0030] When the skin external composition of the present invention is an aqueous solution, the transparency seen from the appearance can be visually observed as described in the following examples in order to evaluate the appearance of insoluble matter.Also, the transmittance can be measured using a spectrophotometer.Specifically, the transmittance can be measured by using a quartz cell with a spectrophotometer (absorbance, for example, 600 nm) using a sample of the skin external composition that has been degassed under reduced pressure.
[0031] The pH of the composition for external use on skin of the present invention is in the range of 2.0 to 8.0, and preferably in the range of 3.0 to 7.0. This pH can be adjusted, for example, by using a pH regulator described below.
[0032] The skin topical composition of the present invention may further contain, but is not limited to, allantoin, ibuprofen piconol, dipotassium glycyrrhizinate, glycyrrhetinic acid, monoammonium glycyrrhizinate, isopropylmethylphenol, chlorhexidine hydrochloride, sulfur, resorcin, etc., as other drugs having anti-inflammatory and bactericidal effects. The content of the other drugs in the skin topical composition of the present invention is not limited to, but is preferably in the range of 0.01 to 5% by mass of the entire composition. The other drugs may be used alone or in combination of two or more.
[0033] In a preferred embodiment of the present invention, the composition for external use on the skin may further contain allantoin. Allantoin is a compound also known as 5-ureidohydantoin, and is a drug known to have anti-inflammatory, cell activating, hemostatic, bactericidal, and antiulcerative effects. The content of allantoin in the composition for external use on the skin of the present invention is not particularly limited, but is preferably contained in the range of 0.01 to 5% by mass, more preferably 0.05 to 2% by mass, of the entire composition.
[0034] The skin topical composition of the present invention may further contain a polyhydric alcohol. The polyhydric alcohol in the present invention is an alcohol having two or more hydroxyl groups in the molecule, which is used in topical preparations for purposes such as solubilizers, bases, moisturizers, thickeners, solvents, and dissolution aids, and examples thereof include propylene glycol, dipropylene glycol, 1,3-butylene glycol, macrogol (also called polyethylene glycol), D-sorbitol, 1,2-pentanediol, 1,2-hexanediol, glycerin, diglycerin, polyglycerin, and polypropylene glycol, which are listed in the Pharmaceutical Additives Dictionary 2016. As the polyhydric alcohol of the present invention, propylene glycol, dipropylene glycol, and 1,3-butylene glycol are preferred. The polyhydric alcohol may be used alone or in combination of two or more.
[0035] The content of the polyhydric alcohol in the composition for external use on skin of the present invention is not particularly limited, but is preferably in the range of 0.5 to 25% by mass of the entire composition, more preferably in the range of 1 to 20% by mass, and even more preferably in the range of 1 to 10% by mass. When two or more kinds of polyhydric alcohols are used, the above content range can be the total content of the two or more kinds of polyhydric alcohols.
[0036] The skin external composition of the present invention may further contain a lower alcohol. The lower alcohol in the present invention is an aliphatic alcohol having 1 to 4 carbon atoms that is used in external preparations for the purposes of solubilizing agents, bases, preservatives, solvents, dissolving aids, etc., such as methanol, ethanol (also called ethyl alcohol), propanol, isopropanol (also called isopropyl alcohol), butyl alcohol, etc. The lower alcohol in the present invention is preferably ethanol or isopropanol, and more preferably ethanol. Ethanol having an ethanol content of 99.5% by volume or more is also called anhydrous ethanol, and this is also included in the ethanol in the present invention. The lower alcohol may be used alone or in combination of two or more.
[0037] The content of the lower alcohol in the topical skin composition of the present invention is not particularly limited, but may be in the range of 0.1 to 40% by mass of the total composition, preferably in the range of 1 to 27% by mass, more preferably in the range of 1 to 10% by mass, and even more preferably in the range of 1 to 5% by mass.
[0038] The skin topical composition of the present invention may be substantially free of lower alcohol. As shown in the examples below, it has been revealed that an aqueous solution containing a combination of salicylic acid and benzethonium chloride produces insoluble matter when the ethanol concentration is low. Specifically, under the conditions of Table 2 in the examples, no insoluble matter was produced at an ethanol concentration of 30%, but insoluble matter was produced at an ethanol concentration of 25% or less. However, the skin topical composition of the present invention, which contains (a) salicylic acid, (b) benzethonium chloride, and (c) one or more nonionic surfactants selected from the group consisting of polyoxyethylene hydrogenated castor oil, polyoxyethylene alkyl ether, and polyoxyethylene polyoxypropylene alkyl ether, does not produce insoluble matter and does not become cloudy even if it does not substantially contain lower alcohol. In this specification, "substantially free of lower alcohol" means that the content of lower alcohol in the entire composition is less than 0.1% by mass. The content of lower alcohol in the entire composition may be 0% by mass.
[0039] The skin topical composition of the present invention can be produced without using ethanol because insoluble matter does not appear and the composition does not become cloudy even if it does not substantially contain ethanol. Therefore, the skin topical composition of the present invention produced without using ethanol can be used by patients who have allergic reactions to ethanol, such as alcohol hypersensitivity, and can be applied to a wide range of patients.
[0040] Pharmaceutical additives other than the above-mentioned components that can be incorporated into the topical skin composition of the present invention are added as necessary for the purpose of further improving the stability of content over time and the feel of use, and examples of such additives include blood circulation improving components, chelating agents, pH adjusting agents, preservatives, gelling agents, thickening agents, oily bases, emulsifiers, moisturizing components, cooling agents, and antioxidants.
[0041] The blood circulation improving component is not particularly limited, but examples thereof include tocopherol acetate, nicotinic acid benzyl ester, etc. The blood circulation improving component may be used alone or in combination of two or more kinds.
[0042] The chelating agent is not particularly limited, but examples thereof include sodium edetate, trisodium ethylenediaminehydroxyethyltriacetate, gluconic acid, phytic acid, tetrasodium hydroxyethanediphosphonate, pyrophosphate, hexametaphosphate, etc. The chelating agent may be used alone or in combination of two or more.
[0043] The pH regulator is not particularly limited, but examples thereof include hydroxides of alkali metals such as sodium hydroxide and potassium hydroxide, alkanolamines such as monoethanolamine, diethanolamine, triethanolamine, monoisopropanolamine, diisopropanolamine, and triisopropanolamine, organic acids such as citric acid, malic acid, tartaric acid, lactic acid, fumaric acid, succinic acid, maleic acid, and acetic acid, and their salts, inorganic acids such as hydrochloric acid, sodium carbonate, sodium hydrogen carbonate, sodium hydroxide, potassium hydroxide, phosphoric acid, trisodium phosphate, sodium hydrogen phosphate, dipotassium phosphate, and potassium dihydrogen phosphate, and their salts, as well as guanidine carbonate, ammonium carbonate, 2-amino-2-methyl-1,3-propanediol, 2-amino-2-hydroxymethyl-1,3-propanediol, and L-arginine. The pH regulator may be used alone or in combination of two or more.
[0044] The preservative is not particularly limited, but examples thereof include benzoic acid, sodium benzoate, ethyl parahydroxybenzoate, propyl parahydroxybenzoate, methyl parahydroxybenzoate, dehydroacetic acid, sodium dehydroacetate, sorbic acid, phenoxyethanol, etc. The preservative may be used alone or in combination of two or more kinds.
[0045] The gelling agent is not particularly limited, but examples thereof include carboxyvinyl polymers, acrylic copolymers, such as acrylate / alkyl acrylate copolymers, polyacrylamides, polysaccharides, etc. The gelling agents may be used alone or in combination of two or more.
[0046] The thickener is not particularly limited, but examples thereof include cellulose derivatives such as methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, carboxymethyl cellulose, and hydroxyethyl cellulose, thickening polysaccharides such as sodium alginate, xanthan gum, carrageenan, guar gum, gelatin, dextrin, cyclodextrin, and pectin, carmellose sodium, polyvinyl alcohol, polyvinylpyrrolidone, sodium polyacrylate, light anhydrous silicic acid, etc. The thickeners may be used alone or in combination of two or more.
[0047] The oily base is not particularly limited, but examples thereof include hydrocarbons such as petrolatum, paraffin, liquid paraffin, light isoparaffin, liquid isoparaffin, ozokerite, ceresin, hard fat, microcrystalline wax, squalane, α-olefin oligomer, and polyethylene powder; higher alcohols such as stearyl alcohol, cetanol, behenyl alcohol, cetostearyl alcohol, hexyldecanol, isostearyl alcohol, octyldodecanol, oleyl alcohol, decyltetradecanol, and myristyl alcohol; ester oils such as isopropyl palmitate, isopropyl myristate, octyldodecyl myristate, cetyl palmitate, glyceryl tri-2-ethylhexylate, and medium-chain fatty acid triglyceride; polymerized silicones such as dimethylpolysiloxane and dimethylsiloxane; and vegetable oils such as olive oil. The oily base may be used alone or in combination of two or more.
[0048] The emulsifier is not particularly limited, but examples thereof include glycerin fatty acid esters, propylene glycol fatty acid esters, polyoxyethylene glycerin fatty acid esters, polyglycerin fatty acid esters, sucrose fatty acid esters, sorbitan fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene sorbit fatty acid esters, polyethylene glycol fatty acid esters, hydrogenated soybean phospholipids, etc. The emulsifiers may be used alone or in combination of two or more.
[0049] The moisturizing component is not particularly limited, but examples thereof include polymeric compounds such as sodium hyaluronate, collagen, elastin, keratin, chitin, and chitosan; amino acids such as glycine, aspartic acid, and arginine; natural moisturizing factors such as sodium lactate, urea, and sodium pyrrolidone carboxylate; and lipids such as ceramide, cholesterol, and phospholipids. The moisturizing component may be used alone or in combination of two or more.
[0050] The cooling agent is not particularly limited, but examples thereof include camphor, dl-camphor, peppermint oil, l-menthol, eucalyptus oil, etc. The cooling agent may be used alone or in combination of two or more kinds.
[0051] The antioxidant is not particularly limited, but examples thereof include ascorbic acid, ascorbic acid glucoside, ascorbyl tetrahexyldecanoate, etc. The antioxidant may be used alone or in combination of two or more kinds.
[0052] The dosage form of the skin external composition of the present invention is not particularly limited, but examples thereof include liquid preparations, creams, ointments, gels, sprays, solid preparations, and patches. These can be produced by using additives and bases suitable for each dosage form as appropriate, according to the usual methods described in the Japanese Pharmacopoeia, etc.
[0053] The topical liquid preparation is a liquid preparation to be applied to the skin, including the scalp, or to nails, and includes liniments and lotions. The topical liquid preparation can usually be produced by adding a solvent, additives, etc. to the active ingredient, dissolving, emulsifying, or suspending it, and filtering it as necessary. The liniment refers to a liquid or muddy topical liquid preparation to be rubbed into the skin. The lotion refers to a topical liquid preparation in which the active ingredient is dissolved, emulsified, or finely dispersed in an aqueous liquid, and can usually be produced by homogenizing the entirety as a solution, suspension, or emulsion using the active ingredient, additives, and purified water.
[0054] Creams are semi-solid preparations that are applied to the skin and are emulsified as oil-in-water or water-in-oil, whereas ointments are semi-solid preparations that are applied to the skin and are made by dissolving or dispersing active ingredients in a base, and are classified into oleaginous ointments and water-soluble ointments.
[0055] Gels are preparations in the form of a gel that are applied to the skin. For example, aqueous gels can be produced by dissolving or suspending an active ingredient in purified water with a polymer compound, other additives, and the like, and then crosslinking the mixture by heating or cooling, or by adding a gelling agent.
[0056] Sprays are preparations in which an active ingredient is sprayed onto the skin in the form of a mist, powder, foam, paste, or the like, and include topical aerosols, pump sprays, etc. Sprays can usually be produced by preparing a solution or suspension of the active ingredient, filtering it as necessary, and then filling it into a container.
[0057] Patches are preparations that are applied to the skin, and include tapes and poultices. In particular, poultices are patches that use a base containing water.
[0058] The skin topical composition of the present invention can be used in the form of a skin topical agent as a medicine, quasi-drug, etc. The skin topical composition of the present invention can be used for anti-acne. In the present invention, anti-acne means use for the purpose of preventing and / or treating acne. The skin topical composition of the present invention contains benzethonium chloride, a bactericidal component, and salicylic acid, a keratin softening component, and benzethonium chloride penetrates the affected area, is effective against acne bacteria and secondary infection causative bacteria, suppresses keratin hyperplasia caused by acne, and inhibits the worsening of acne. It can be used for acne that is just starting to form or acne that has hardened.
[0059] The skin external composition of the present invention can be applied to affected skin areas once to several times a day. For example, an appropriate amount can be applied to a desired area from a container such as a bottle, jar, tube, pump, stick, roll-on, or aerosol directly, or after taking an appropriate amount on the hand, cotton wool, or gauze. More specifically, it can be used twice a day (morning and evening) by taking an appropriate amount on cotton wool or gauze and pressing it against the skin for a while (2 to 3 minutes). It can be used on areas where acne may occur, such as the face, back, shoulders, chest, upper arms, and neck.
[0060] To store the topical skin composition of the present invention, there can be used, without particular limitation, plastic containers including polyolefin containers such as polypropylene and polyethylene, and polyester containers such as polyethylene terephthalate, glass containers, and metal containers such as aluminum.
[0061] The present invention will now be described in more detail with reference to examples. EXAMPLES
[0062] 1. Example of manufacturing a composition for external use on skin (1) Reagents A skin topical composition was prepared using the following reagents: Salicylic acid (Fujifilm Wako Pure Chemical Industries, Ltd.) Benzethonium chloride (Fujifilm Wako Pure Chemical Industries, Ltd.) Allantoin (Tokyo Chemical Industry Co., Ltd.) Absolute ethanol (Imazu Pharmaceutical Co., Ltd.) Dipropylene glycol (Kanto Chemical Co., Ltd.) 1,3-Butylene glycol (Kanto Chemical Co., Ltd.) Propylene glycol (Maruishi Pharmaceutical Co., Ltd.)
[0063] Polyoxyethylene (20) Polyoxypropylene (4) Cetyl Ether (NIKKOL PBC-34, Nikko Chemicals Co., Ltd.) Polyoxyethylene (20) Polyoxypropylene (8) Cetyl Ether (NIKKOL PBC-44, Nikko Chemicals Co., Ltd.) Polyoxyethylene lauryl ether (NIKKOL BL-9EX, BL-21, Nikko Chemicals Co., Ltd.) Setomacrogol 1000 (NIKKOL BC-23, Nikko Chemicals Co., Ltd.)
[0064] Polyoxyethylene cetyl ether (NIKKOL BC-20, BC-30, Nikko Chemicals Co., Ltd.) Polyoxyethylene oleyl ether (NIKKOL BO-20V, Nikko Chemicals Co., Ltd.) Polyoxyethylene behenyl ether (NIKKOL BB-20, Nikko Chemicals Co., Ltd.) Polyoxyethylene hydrogenated castor oil 60 (NIKKOL HCO-60, Nikko Chemicals Co., Ltd.) Polysorbate 60 (NIKKOL TS-10MV, Nikko Chemicals Co., Ltd.) Polysorbate 80 (NIKKOL TO-10MV, Nikko Chemicals Co., Ltd.)
[0065] Polyoxyethylene sorbitol tetraoleate (NIKKOL GO-460V, Nikko Chemicals Co., Ltd.) Polyethylene glycol monostearate (NIKKOL MYS-40V, Nikko Chemicals Co., Ltd.) Polyglyceryl monostearate (NIKKOL Decaglyn 1-SVEX, Nikko Chemicals Co., Ltd.) Citric acid (Tokyo Chemical Industry Co., Ltd.) Sodium citrate hydrate (Kanto Chemical Co., Ltd.)
[0066] (2) Manufacturing method
[0067] At room temperature, salicylic acid and benzethonium chloride were dissolved by adding ethanol and / or polyhydric alcohol and / or a surfactant melted by heating, and purified water containing a dissolved pH adjuster was added to this liquid and thoroughly stirred to obtain a composition for topical skin application.
[0068] (3) Transparency evaluation of topical skin compositions The transparency of the obtained external skin composition immediately after production was visually confirmed, and the appearance of insoluble matter was evaluated according to the following criteria. <Evaluation criteria> ○: No insoluble matter was observed ×: The composition is cloudy and not transparent due to the appearance of insoluble matter. (4) Storage stability test of topical skin composition The obtained composition for external use on the skin was allowed to stand at room temperature for 24 hours, and the transparency was visually confirmed and evaluated according to the same criteria as above.
[0069] (5) Solubility of Salicylic Acid and Benzethonium Chloride The solubilities of the active ingredients, salicylic acid and benzethonium chloride, are shown as reference examples in Table 1. The solubility of allantoin is also shown in Table 1.
[0070] [Table 1]
[0071] Salicylic acid is insoluble in water, but benzethonium chloride salt and allantoin are soluble in water (Reference Examples 1 to 3). The salicylic acid in Reference Example 1 was not soluble at all.
[0072] In the 22% ethanol solution, salicylic acid, benzethonium chloride, and allantoin did not produce insoluble matter when used alone, but the combination of salicylic acid and benzethonium chloride produced insoluble matter and the solution became cloudy immediately after production. It was not previously known that the combination of salicylic acid and benzethonium chloride would produce insoluble matter in an ethanol solution.
[0073] The ethanol concentration was varied to examine the conditions under which insoluble matter would be produced by the combination of salicylic acid and benzethonium chloride. The results are shown in Table 2.
[0074] [Table 2]
[0075] It was revealed that insoluble matter was generated when the ethanol concentration in the aqueous solution was low. Under the conditions in Table 2, no insoluble matter was generated at an ethanol concentration of 30%, but insoluble matter was generated at an ethanol concentration of 25% or less.
[0076] (6) Effect of surfactants on the solubility of salicylic acid and benzethonium chloride The solubility of the compound in aqueous solutions with ethanol concentrations of 1 to 25% was examined by adding a surfactant. The results are shown in Table 3.
[0077] [Table 3]
[0078] It was revealed that the combination of salicylic acid and benzethonium chloride did not produce insoluble matter in aqueous solutions with ethanol concentrations of 1 to 25% in the presence of a surfactant.
[0079] The effects of adding various surfactants were examined in an aqueous solution containing 10% ethanol and 5% dipropylene glycol. The results are shown in Table 4.
[0080] [Table 4]
[0081] In Examples 6 to 8, in which polyoxyethylene polyoxypropylene alkyl ether, polyoxyethylene alkyl ether, or polyoxyethylene hydrogenated castor oil was used, no insoluble matter was generated immediately after production or even after 24 hours.
[0082] The effects of adding various surfactants were examined in an aqueous solution containing 4% ethanol and 4% dipropylene glycol. The results are shown in Table 5.
[0083] [Table 5]
[0084] In Examples 9 to 16, in which polyoxyethylene polyoxypropylene alkyl ether, polyoxyethylene alkyl ether, or polyoxyethylene hydrogenated castor oil was used, no insoluble matter was generated immediately after production or after 24 hours. In Comparative Examples 1 to 4, in which polysorbate 60, polyoxyethylene sorbitol tetraoleate, polyethylene glycol monostearate, or polyglyceryl monostearate was used, insoluble matter was generated immediately after production or after 24 hours. Although not shown in Table 5, insoluble matter was generated 24 hours after production for polysorbate 60, polyoxyethylene sorbitol tetraoleate, polyethylene glycol monostearate, or polyglyceryl monostearate, even when the amount of each was increased to 2%.
[0085] The effect of pH on the solubility of salicylic acid and benzethonium chloride was examined. In the following Examples 17 to 19, 1,3-butylene glycol was used as the polyhydric alcohol. The results are shown in Table 6.
[0086] [Table 6] No effect of pH on the solubility of salicylic acid and benzethonium chloride was observed in the pH range of 3-5.
[0087] (7) Study of solubility in ethanol-free formulations The solubility of the compound in an aqueous solution containing no ethanol was examined in the presence of various surfactants, and the results are shown in Tables 7 and 8.
[0088] [Table 7]
[0089] [Table 8]
[0090] In Examples 20 to 33, in which polyoxyethylene polyoxypropylene alkyl ether, polyoxyethylene alkyl ether, or polyoxyethylene hydrogenated castor oil was used, no insoluble matter was generated immediately after production or after 24 hours, even when no ethanol was contained. In Comparative Example 5, in which no surfactant was added, insoluble matter was generated immediately after production or after 24 hours. At least in the acidic range of pH 3.0 to 5.5, no effect of pH on the solubility of salicylic acid and benzethonium chloride was observed.
[0091] (8) Manufacturing example of external liquid preparation A manufacturing example of a liquid preparation for external use is shown in Table 9. Using the ingredients and amounts shown in Table 9, a liquid preparation for external use can be manufactured in accordance with the section on "Liquid Preparations for External Use" in the General Provisions for Preparations of the Japanese Pharmacopoeia.
[0092] [Table 9]
[0093] (9) Gel manufacturing example A manufacturing example of a gel formulation is shown in Table 10. A gel formulation can be manufactured using the ingredients and amounts shown in Table 10 in accordance with the section on "gels" in the General Provisions for Preparations of the Japanese Pharmacopoeia.
[0094] [Table 10]
[0095] (10) Manufacturing example of cream A manufacturing example of a cream formulation is shown in Table 11. A cream formulation can be manufactured using the ingredients and amounts shown in Table 11 in accordance with the section on "Cream Formulations" in the General Provisions for Preparations of the Japanese Pharmacopoeia.
[0096] [Table 11] [Industrial Applicability]
[0097] The composition for external use on the skin containing salicylic acid and benzethonium chloride of the present invention is extremely useful because it has an excellent feel when used and has excellent storage stability as measured by appearance when stored at room temperature.
Claims
1. (a) salicylic acid, (b) benzethonium chloride, and (c) one or more nonionic surfactants selected from the group consisting of polyoxyethylene hydrogenated castor oil, polyoxyethylene polyoxypropylene alkyl ether, and polyoxyethylene alkyl ether having an alkyl group with 14 to 22 carbon atoms; and further comprising a lower alcohol concentration of 27% by mass or less in the entire composition. Anti-acne skin topical composition.
2. 2. The anti-acne skin topical composition according to claim 1, wherein the content of component (a) is 0.1 to 1% by mass, the content of component (b) is 0.01 to 0.5% by mass, and the content of component (c) is 0.1 to 6% by mass, based on the total weight of the composition.
3. The anti-acne skin topical composition according to claim 1 or 2, wherein the content of the nonionic surfactant is 1 to 6 mass% of the total skin topical composition.
4. The anti-acne skin topical composition according to any one of claims 1 to 3, wherein the concentration of the lower alcohol in the entire composition is 1 to 25% by mass.
5. The anti-acne skin topical composition according to any one of claims 1 to 3, wherein the concentration of the lower alcohol in the entire composition is less than 0.1% by mass.
6. The anti-acne skin topical composition according to any one of claims 1 to 5, further comprising allantoin.
7. The anti-acne skin topical composition according to any one of claims 1 to 6, further comprising a polyhydric alcohol.
8. The anti-acne skin composition for external use according to any one of claims 1 to 7, which is in the form of a liquid for external use, a cream, an ointment, a gel, a spray, a solid for external use, or a patch.
9. The anti-acne skin topical composition according to any one of claims 1 to 7, which is in the form of a liquid for topical application.
10. The anti-acne skin topical composition according to any one of claims 1 to 9, which is contained in a polyolefin container.
Citation Information
Patent Citations
JP1975047476A
Cosmetic for pimple
JP1986072707A
Preparation for external use for Anti-acne vulgaris
JP1998087496A
Skin care medicinal composition
JP2001187741A
Preservative mixture containing quaternary ammonium compounds
JP2004524320A
